U.S. UNFRACTIONATED HEPARIN MARKET ANALYSIS

Market Challenges And Opportunities

Increasing cases of thrombosis and adoption of strategies such as mergers and collaborations by market players are expected to drive the market growth

The U.S. is expected to exhibit growth in the market, owing to increasing cases of deep-vein thrombosis (DVT). For instance, according to the National Center for Biotechnology Information (NCBI), the study published in 2018 reported that in the U.S., 200,000 people develop venous thrombosis annually and of those, 50,000 cases are complicated by pulmonary embolism. It is expected that the annual incidence of deep-vein thrombosis (DVT) is 80 cases per 100,000 with a prevalence of lower limb deep-vein thrombosis (DVT) in 1 case per 1,000 population.

Moreover, in 2014, the American Society of Health-System Pharmacists (ASHP) issued the policy for safe and effective use of heparin in neonatal care, which was reviewed by the Council on Therapeutics and by the Board of Directors.